^
Association details:
| Biomarker: | PD-L1 expression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
2304 Impact of Programmed Death-Ligand 1 (PD-L1) Expression on The Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Published date:
11/01/2020
Excerpt:
PD-L1-positive tumors was significantly associated with worse PFS outcomes compared to PD-L1-negative tumors...Patients with PD-L1-positive tumors was associated with worse progression-free survival outcomes compared to those with PD-L1-negative tumors in metastatic EGFR-mutated NSCLC, when particularly treated with older generations of EGFR TKI as first-line therapy.
